{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T07:01:02Z","timestamp":1780902062543,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.pupt.2026.102420","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:09:43Z","timestamp":1773126583000},"page":"102420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9630-8855","authenticated-orcid":false,"given":"Esen Deniz","family":"Akman Ar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-8727","authenticated-orcid":false,"given":"Nadir","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7143-3260","authenticated-orcid":false,"given":"U\u011fur","family":"Balaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6071-0851","authenticated-orcid":false,"given":"O\u011fuz","family":"Karc\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6250-2100","authenticated-orcid":false,"given":"Ebru","family":"Damado\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7475-3775","authenticated-orcid":false,"given":"Ali Fuat","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6427-5826","authenticated-orcid":false,"given":"Kutay","family":"Demirkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.pupt.2026.102420_bib1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: a review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.pupt.2026.102420_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.japh.2018.01.006","article-title":"The pharmacist's role in supporting people living with cystic fibrosis","volume":"58","author":"Abraham","year":"2018","journal-title":"J. Am. Pharmaceut. Assoc."},{"key":"10.1016\/j.pupt.2026.102420_bib3","article-title":"Measurement of treatment burden in cystic fibrosis: a systematic review","author":"Altabee","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.pupt.2026.102420_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.12.009","article-title":"Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes","volume":"12","author":"Sawicki","year":"2013","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.pupt.2026.102420_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ppul.21325","article-title":"Longitudinal assessment of health\u2010related quality of life in an observational cohort of patients with cystic fibrosis","volume":"46","author":"Sawicki","year":"2011","journal-title":"Pediatr. Pulmonol."},{"issue":"9","key":"10.1016\/j.pupt.2026.102420_bib6","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1345\/aph.1D479","article-title":"Development and validation of the medication regimen complexity index","volume":"38","author":"George","year":"2004","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.pupt.2026.102420_bib7","first-page":"248","article-title":"Association of medication regimen complexity with clinical endpoints in pediatric patients with cystic fibrosis","volume":"26","author":"Tjugum","year":"2021","journal-title":"J. Pediatr. Pharmacol. Therapeut."},{"issue":"5","key":"10.1016\/j.pupt.2026.102420_bib8","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/jep.12526","article-title":"Validation of the Turkish version of medication regimen complexity index among elderly patients","volume":"22","author":"Okuyan","year":"2016","journal-title":"J. Eval. Clin. Pract."},{"issue":"10212","key":"10.1016\/j.pupt.2026.102420_bib9","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pupt.2026.102420_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jcf.2020.11.008","article-title":"GOAL-e2 Investigators. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation","volume":"20","author":"Guimbellot","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.pupt.2026.102420_bib11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jcf.2022.05.005","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis","volume":"21","author":"Song","year":"2022","journal-title":"J. Cyst. Fibros.: Off.J. European Cystic Fibrosis Soc."},{"issue":"11","key":"10.1016\/j.pupt.2026.102420_bib12","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1513\/AnnalsATS.202407-694ED","article-title":"Reducing treatment burden in cystic fibrosis: is there a risk to OverSIMPLIFYing therapies?","volume":"21","author":"Quon","year":"2024","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.pupt.2026.102420_bib13","doi-asserted-by":"crossref","DOI":"10.3310\/nihropenres.13260.1","article-title":"Exploring the nature of perceived treatment burden: a study to compare treatment burden measures in adults with cystic fibrosis","volume":"2","author":"Altabee","year":"2022","journal-title":"NIHR Open Res."},{"key":"10.1016\/j.pupt.2026.102420_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(24)00118-8","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on utilization of routine therapies in cystic fibrosis: danish nationwide register study","author":"R\u00e5ket","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.pupt.2026.102420_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"167","key":"10.1016\/j.pupt.2026.102420_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0154-2022","article-title":"Role of inhaled antibiotics in the era of highly effective CFTR modulators","volume":"32","author":"Elborn","year":"2023","journal-title":"Eur. Respir. Rev."},{"issue":"4","key":"10.1016\/j.pupt.2026.102420_bib17","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jcf.2022.06.005","article-title":"The impact of modulator therapies on pancreatic exocrine function: the good, the bad and the potentially ugly","volume":"21","author":"Freeman","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"12","key":"10.1016\/j.pupt.2026.102420_bib18","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.14309\/ajg.0000000000001527","article-title":"Cystic fibrosis transmembrane conductance regulator modulator use is associated with reduced pancreatitis hospitalizations in patients with cystic fibrosis","volume":"116","author":"Ramsey","year":"2021","journal-title":"Off.J.Am College Gastroenterol. ACG."},{"issue":"7","key":"10.1016\/j.pupt.2026.102420_bib19","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/ppul.25361","article-title":"Assessment of treatment burden and complexity in cystic fibrosis: a quality improvement project","volume":"56","author":"Hente","year":"2021","journal-title":"Pediatr. Pulmonol."},{"issue":"6","key":"10.1016\/j.pupt.2026.102420_bib20","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment preference among people with cystic fibrosis: the importance of reducing treatment burden","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.pupt.2026.102420_bib21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jcf.2019.11.007","article-title":"Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy","volume":"19","author":"Gifford","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"15","key":"10.1016\/j.pupt.2026.102420_bib22","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.3390\/jcm13154491","article-title":"CFTR modulators therapy efficacy in reducing Cystic Fibrosis (CF) exacerbation and improving selected spirometry parameters: a real-life study in a single-centre Polish population","volume":"13","author":"Winiarska","year":"2024","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.pupt.2026.102420_bib23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1183\/23120541.00170-2022","article-title":"The long-term effects of insulin use in incident cystic fibrosis-related diabetes: a target trial emulated using longitudinal national registry data","volume":"8","author":"Granger","year":"2022","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.pupt.2026.102420_bib25","article-title":"Adamoli A, Bakkeheim E, van Rens J et al","author":"Zolin","year":"2024","journal-title":"ECFSPR Annual Rep.2022"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553926000131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553926000131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:47:47Z","timestamp":1780901267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553926000131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"alternative-id":["S1094553926000131"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2026.102420","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2026.102420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102420"}}